Watch Dr. Mark R. Barakat delve into the ALTITUDE Trial, a year-long investigation that shows improvement for Diabetic Retinopathy patients. Learn more about this study and watch the full interview from MedPage Today.
Dr. Mark Barakat discusses how clinical trials are helping patients maintain their vision. Read the Article on AZCentral
Watch Dr. Mark Barakat discuss the suprachoroidal delivery of a tyrosinase kinase inhibitor and a gene therapy agent for the treatment of neovascular AMD.
Watch Dr. Mark R. Barakat sit down with CBS to talk about being the first in AZ to administer gene therapy to treat Age-related Macular Degeneration. Watch the CBC Interview!
Watch Dr. Mark R. Barakat discuss the results of the Kingfisher trail, a study employing broluizumab for the treatment of diabetic macular edema with Retina Synthesis.
Watch Dr. Mark R. Barakat be interviewed by Nathan Steinle, MD from California Retina Consultants following his presentation at the virtual 2020 ASRS convention. In his presentation, Dr. Barakat discusses the Kodiac trials currently undergoing at the Retinal Research Institute.
CINCINNATI–(BUSINESS WIRE)– Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced new results from the fifth cohort of subjects from a Phase 1b trial of a topical ocular formulation of AKB-9778 providing evidence of tolerability and IOP reduction from patients […]
Watch Dr. Mark R. Barakat on Arizona AZTV to discuss retinal detachments and what treatment options are available today. A retinal detachment occurs when the retina separates from the wall of the eye. As we age, the vitreous gel that fills the eye begins to liquefy and pulls away from the back of the eye. […]
Karen Mulligan, PhD1,6; Seth A. Seabury, PhD2,6; Pravin U. Dugel, MD3,4; et al Key Points Question How much economic value do anti–vascular endothelial growth factor (anti-VEGF) treatments generate for patients with wet age-related macular degeneration and society in the United States? Findings In this economic evaluation study, visual acuity improvement associated with anti-VEGF treatments generated $5.1 billion to $8.2 billion in […]
Neovascular AMD Pravin U. Dugel, MD What up-and-coming therapies for wet AMD are you most excited about and why? The therapies currently being investigated for neovascular age-related macular degeneration (nvAMD) can be stratified into 3 silos: better short-term efficacy, better long-term efficacy, and increased durability. The majority of drugs in the pipeline have focused on […]